IO BIOTECH
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
IO BIOTECH
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-12-23
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.iobiotech.com
Total Employee:
11+
Status:
Active
Contact:
(452)194-7856
Email Addresses:
[email protected]
Total Funding:
175.01 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Mobile Non Scaleable Content Nginx
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
amcure
amcure is a clinical-stage company develops peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.
aratinga.bio
aratinga.bio is a preclinical-stage biotech company developing novel immunotherapies to treat cancer.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
EiRx Therapeutics
EiRx Therapeutics operates as a research-driven healthcare company developing targeted therapies for the treatment of cancer.
GamaMabs Pharma
GamaMabs Pharma is a clinical-stage immuno-oncology company that developes optimized therapeutic antibodies for the treatment of cancer.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Innoskel
InnoSkel is a pioneering platform biotechnology company developing therapies for rare skeletal diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
NorthSea Therapeutics
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
SNIPR Biome
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Xeltis
Xeltis is a clinical-stage medtech company with the world’s most advanced polymer-based platform of restorative cardiovascular devices.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - IO Biotech
Serrado Capital
Serrado Capital investment in Series B - IO Biotech
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - IO Biotech
Lundbeckfonden Emerge
Lundbeckfonden Emerge investment in Series B - IO Biotech
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series B - IO Biotech
Idinvest Partners
Idinvest Partners investment in Series B - IO Biotech
Vivo Capital
Vivo Capital investment in Series B - IO Biotech
Novo Holdings
Novo Holdings investment in Series B - IO Biotech
Kurma Partners
Kurma Partners investment in Series B - IO Biotech
EIR Ventures
EIR Ventures investment in Series B - IO Biotech
Official Site Inspections
http://www.iobiotech.com Semrush global rank: 9.5 M Semrush visits lastest month: 145
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IO Biotech"
IO Biotech - Crunchbase Company Profile & Funding
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology …See details»
IO Biotech, Inc. - Governance - Board of Directors
During his career, he was o.a. President of the the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and President of ECCO (European CanCer Organization) from 2008 to 2010, and …See details»
IO Biotech, Inc. - Governance - Executive Management
Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade …See details»
IO Biotech, Inc. (IOBT) Company Profile & Facts - Yahoo Finance
See the company profile for IO Biotech, Inc. (IOBT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
IO Biotech - LinkedIn
IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of ...See details»
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) - IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer …See details»
Science - IO Biotech
Nov 7, 2024 During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from 2008 to 2010. He is currently President of the …See details»
IO Biotech - Overview, News & Similar companies | ZoomInfo.com
May 16, 2024 iobiotech.com. Revenue $14.8 Million. Stock Symbol IOBT. Industry Business Services General Business Services . Most Recent Scoops. May 17 2024. Earnings. May 17 …See details»
IO Biotech Expands Senior Leadership Team to Progress …
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modu...See details»
IO Biotech, Inc. - IO Biotech Expands Senior Leadership Team to ...
Apr 15, 2024 For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X . Forward-Looking Statement. This press release contains …See details»
IO Biotech Announces Participation in Upcoming Investor …
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on …See details»
IO Biotech Announces New Clinical Collaboration with Merck
Nov 3, 2022 [email protected]. Investor Contact: Corey Davis, Ph.D. LifeSci Advisors +1 212-915-2577 [email protected]. Media Contact: Raena Mina, Ph.D. LifeSci …See details»
Careers - IO Biotech
During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from 2008 to 2010. …See details»
IO Biotech, Inc. - IO Biotech Reports First Quarter 2024 Financial ...
May 14, 2024 Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational …See details»
IO Biotech, Inc. (IOBT) Stock Price, Quote & News - Stock Analysis
5 days ago Website https://www.iobiotech.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 3 analysts, the average rating for IOBT …See details»
Posters & Publications - IO Biotech
Nov 8, 2022 During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from …See details»
IO Biotech, Inc. - IO Biotech Reports its Off-the-Shelf Therapeutic ...
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X . Forward-Looking Statement. This press release contains forward-looking …See details»
A randomized Phase 2 trial of the IO102-IO103 (IDO and PD-L1)
Title: 1201861 IOB-032_ASCO 2024_Trials in Progress Poster_RGB_ePoster_HR PDF Author: Lara Wilson Created Date: 5/20/2024 11:39:16 AMSee details»
Programs - IO Biotech
IO112 is our wholly owned, novel T-win® vaccine candidate that is designed to activate and expand T cells specific for arginase-1. Arginase-1 is highly expressed by difficult-to-treat …See details»